✦ LIBER ✦

Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin for locally advanced transitional cell carcinoma of the bladder

✍ Scribed by Ralph J. Miller Jr.; Robert R. Bahnson; Barbara Banner; Marc S. Ernstoff; Walter F. O'donnell

Publisher: John Wiley and Sons
Year: 1990
Tongue: English
Weight: 376 KB
Volume: 65
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19900115)65:2<207::aid-cncr2820650204>3.0.co;2-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of neoadjuvant methotre

A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma

✍ Louise E. Morrell; Young J. Lee; Judith Hurley; Mayda Arias; Carolyn Mies; Steph 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

## Background: Traditionally, primary surgical therapy is considered unsuitable for the treatment of patients with locally advanced breast carcinoma (labc). multiple reports have documented the efficacy of primary chemotherapy in this group of patients. the purpose of this study was to investigate

Phase II trial of intermediate dose meth

Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma

✍ Paul M. Dodd; John A. McCaffrey; Madhu Mazumdar; Howard Scher; Vaia Vlamis; Gera 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views

## Background: This study was undertaken to determine whether the use of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin as first-line therapy increases the proportion of major responders and overall survival in patients with unresectable or metastatic tra

A phase II trial of cisplatin, methotrex

A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck

✍ Francesco Caponigro; Pasquale Comella; Paolo Marcolin; Francesco Russo Spena; Ma 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Background: Induction chemotherapy in locoregionally advanced squamous cell carcinoma of the head and neck (scchn) might improve survival with respect to radiation therapy alone. furthermore, chemotherapy represents the only therapeutic option in metastatic head and neck carcinoma. ## Methods:

Ifosfamide, paclitaxel, and cisplatin fo

Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract : Final report of a Phase II trial evaluating two dosing schedules

✍ Dean F. Bajorin; John A. McCaffrey; Paul M. Dodd; Susan Hilton; Madhu Mazumdar; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

## BACKGROUND. A combination regimen of ifosfamide, paclitaxel, and cisplatin (ITP), recycled every 4 weeks, was reported in the treatment of previously untreated patients with advanced transitional cell carcinoma (TCC). This study sought to examine ITP at 3-week intervals to assess its feasibility